Information Provided By:
Fly News Breaks for February 20, 2020
AMED
Feb 20, 2020 | 07:54 EDT
SunTrust analyst David MacDonald raised his price target on Amedisys to $225 and kept his Buy rating after its Q4 earnings beat and FY20 guidance. The analyst says the quarter was highlighted by the company's solid organic trends, robust cash flow, and margin expansion, adding that its industry drivers are "meaningful" and its strategic position remains "enviable".
News For AMED From the Last 2 Days
AMED
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.